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Resumo 
Danos nas fibras nervosas periféricas resultam em perda axonal e desmielinização, 
seguidos de regeneração e remielinização sob condições ideais com a possibilidade de alguma 
recuperação funcional. Estudos recentes indicam que a diferença na regeneração axonal 
entre o sistema nervoso periférico (PNS) e o sistema nervoso central (CNS) resulta da 
presença de fatores permissivos presentes no PNS e fatores inibitórios ativos presentes no 
CNS. 
Pacientes com lesões no nervo periférico estão muitas vezes no auge da sua atividade 
laboral, o que faz da regeneração do nervo periférico um foco principal de pesquisa. Assim, o 
desafio experimental consiste em acelerar a regeneração axonal para promover a reinervação 
e melhorar a recuperação funcional após uma lesão no nervo periférico. Algumas das 
abordagens experimentais para melhorar a recuperação funcional incluem a aplicação focal 
de fatores neurotróficos, o bloqueio de moléculas inibidoras da regeneração axonal e o 
transplante de células. 
Depois de ocorrer uma lesão quer de axonotmese quer de neurotmese, os axónios 
periféricos têm a capacidade de se regenerar e de se ligar novamente aos seus alvos, sendo 
que no primeiro caso não há necessidade de reconstrução cirúrgica uma vez que o endoneuro, 
perineuro e epineuro são mantidos. No entanto, o estado funcional resultante pode não ser o 
melhor uma vez que a regeneração é demorada e conduz à atrofia neurogénica dos músculos 
regionais. Na prática clínica, a reparação cirúrgica ideal em situações de neurotmese 
(seccionamento total do nervo) considera-se ser a sutura topo-a-topo, de modo a aproximar o 
topo distal do topo proximal, sem haver tensão no local da sutura. Alternativamente, nervos 
autólogos são o gold standard deste tipo de procedimentos sempre que ocorre perda de 
substância e não seja possível executar uma sutura topo-a-topo sem tensão. No entanto, o 
uso de autoenxertos está limitado pelos inconvenientes inerentes uma vez que requer uma 
segunda cirurgia, com sacrifício de um nervo funcional, o que resulta em perda sensorial e 
morbidade do local de doação, entre outros. 
Nas últimas décadas, os diferentes tipos de enxertos artificiais ou biológicos foram 
desenvolvidos e investigados para que pudesse ser estabelecida uma relação entre eles e os 
enxertos de nervos autólogos em termos dos resultados da regeneração do nervo e da 
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recuperação funcional. Estes tubos-guia são projetados para preencher a lacuna existente 
num nervo seccionado quando existe um gap, para limitar a fibrose e orientar as fibras em 
regeneração na direção do topo distal. O enxerto de nervo artificial é um canal tubular feito 
de materiais sintéticos ou biodegradáveis e que pode orientar a regeneração do axónio sem 
inibir o crescimento e maturação. O canal tubular pode ser implantado vazio ou preenchido 
com fatores de crescimento, células ou fibras. Devido à sua capacidade de renovação, 
multiplicação e diferenciação, as células estaminais mesenquimatosas (MSCs) têm sido usadas 
para suplementar os tubos-guia, sendo que foi já demonstrado que estas se podem diferenciar 
em células neuronais e células da glia. 
Em termos de design, os tubos-guia são semelhantes e podem ser feitos de diferentes 
biomateriais, sejam eles naturais, tais como o alginato ou o quitosano, ou sintéticos, tal como 
o ácido poliglicólico (PGA), utilizando diferentes métodos de fabricação. 
O quitosano é amplamente utilizado para aplicações biomédicas, devido à sua 
biocompatibilidade e atividade antibacteriana e também pode ser associado com outros 
produtos de acordo com a necessidade da aplicação. Neste trabalho, foram produzidos tubos-
guia de quitosano sendo que se procedeu à sua implantação no modelo animal do nervo 
ciático de ratos adultos. Foram feitos teses funcionais assim como uma caraterização 
mecânica e estrutural dos tubos-guia. 
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Abstract 
Damage to peripheral nerve fibers results in axonal loss and demyelination followed by 
regeneration and remyelination under optimal conditions with the possibility of some 
functional recovery. Recent studies indicate that the difference between peripheral nervous 
system (PNS) and central nervous system (CNS) axonal regeneration is the result of both 
permissive factors present in the PNS and active inhibitory factors present in the CNS. 
Patients with peripheral nerve injury are often at the peak of their employment 
productivity which makes peripheral nerve regeneration a prime focus of research. Hence, 
the experimental challenge is to accelerate axonal regeneration to promote reinnervation and 
improve functional recovery after peripheral nerve injury. Some of the experimental 
approaches to enhance functional recovery include focal application of neurotrophic factors, 
blockade of axonal regeneration inhibitory molecules and cell transplantation. 
After an injury, whether it is one of axonotmesis or one of neurotmesis, peripheral axons 
have the ability to regenerate themselves and to reconnect with their targets. In the first 
case, there is no need to perform a surgical reconstruction because the endoneurium, 
perineurium and epineurium structure is maintained. However, the functional outcome may 
not be the best since the regeneration process takes a long time and it leads to neurogenic 
atrophy of the regional muscles. In clinical practice, the ideal surgical repair in neurotmesis 
cases (complete sectioning of the nerve) is considered to be the end-to-end coaptation, by 
closing the distance between the proximal and the distal stumps, without associated tension 
in the suture. Alternatively, autologous nerves are the gold standard in this type of 
procedures every time there is loss of matter and if it is not possible to perform an end-to-
end suture without tension. However, autograft nerve grafting is limited by the inherent 
drawbacks since it requires a second surgery, with sacrifice of a functional nerve, which 
results in donor sensory loss and pain and donor site morbidity, among others. 
In the past few decades, different types of biological or artificial grafts have been 
developed and investigated so a comparison could be established between them and the 
autologous nerve grafts in terms of the outcomes of nerve regeneration and functional 
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recovery. These guide tubes are designed to bridge the gap of a sectioned nerve, to limit the 
fibrosis process and to orient the regenerating fibers towards the distal stump. The artificial 
nerve graft is a tubular conduit of synthetic or biodegradable materials, which could guide 
axon regeneration without inhibiting growth and maturation. The conduit may be implanted 
empty or it may be filled with growth factors, cells or fibers. Due to their ability to renovate, 
multiply and differentiate, mesenchymal stem cells (MSCs) have been used to supplement 
guide tubes being that it has already been demonstrated that they can differentiate into 
neuronal and glial cells. 
In terms of design, the guide tubes are similar but they can be made of different 
biomaterials, whether they are natural, such as alginate or chitosan, or synthetic, such as 
polyglycolic acid (PGA), using various fabrication methods. 
Chitosan is widely used for biomedical applications because of its biocompatibility and 
antibacterial activity and it can also be assembled with many other products, depending on 
the need of the application. In this work, chitosan guide tubes were produced and implanted 
using the rat sciatic nerve animal model. Functional tests were performed as well as a 
mechanical and structural characterization of the guide tubes. 
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Chapter 1 
 
Introduction 
It is estimated that about 2.8% of trauma patients, many of whom acquire life-long 
disability, are affected by peripheral nerve injuries. In Europe, over 300,000 cases of 
peripheral nerve injury occur annually and in the United States approximately 360,000 people 
suffer from upper extremity paralytic syndromes annually.1,2,3 
Peripheral nerve lesions are caused primarily by traffic accidents, tumour resection or 
side effects resulting from surgeries like orthopaedic and cosmetic facial interventions.4 
Unlike what happens in the central nervous system (CNS) of mammals, the peripheral nervous 
system (PNS) has a permissive environment provided by the Schwann cells, whereas the CNS 
has active inhibitory factors that elicit growth cone collapse.5 Recent works have shown that 
the PNS has an intrinsic regenerative ability to a certain extent.1 
The regeneration of peripheral nerves has been a field of study for many years and an 
accelerated development has been seen in finding new and better strategies to repair 
peripheral nerves. However, the clinical application of state-of-the-art approaches is still 
limited, being that the most relevant functional outcomes are not completely satisfactory 
and depend on many factors including the size and location of injured nerves as well as the 
age of patients.1 
Peripheral nerve injuries may include or not gaps between the nerve stumps. If when an 
injury occurs an intervention is not made, functional regeneration becomes restricted due to 
scars, neuroma formation, mismatched fibers or extensive splitting of the re-growing axons.6 
Axonotmesis involves severance or destruction of peripheral nerves without any damage to 
connective tissue such as the endoneurial tubes, which remain intact. The interruption of 
axons is the result of nerve pinching, crushing or prolonged pressure.2 In neurotmesis the 
nerve is completely transected, being that nerve loss may or not occur. Without a surgical 
reconstruction the axonal regrowth is impossible, making this the most challenging type of 
peripheral nerve injury repair.6,2 
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The main challenges, when facing surgical management of the injury, is the survival of 
the damaged neurons, the establishment of a microenvironment that eases the neurite 
outgrowth and the guidance of axons to their target for appropriate reinnervation.1 
Furthermore, microsurgical methods of treatment have been shown to be very effective 
despite the residual disability that often persists for the lifetime of the patient.4 Thus, there 
is a clear need to understand the fundamental events that occur during an injury and the 
cellular and molecular requirements for a successful nerve regeneration process.2,7 
The tissue engineering approach is to repair, complement and regenerate damaged tissue 
by using materials that will support and reinforce the regenerating tissue. One of the 
strategies is to build three-dimensional, porous scaffolds which role is to manipulate cell 
functions since they provide spaces and surface area enough for cell adhesion and 
proliferation, and to supply oxygen and nourishment. Besides these characteristics, scaffolds 
should be biocompatible and biodegradable, have a large surface to volume ratio, and be 
mechanically strong and capable of being formed into desired shapes and structures.8 
In the case of peripheral nerve injury, tissue engineering often associates biomaterials, 
such as chitosan and PCL, to cellular systems, which should be helpful to improve nerve 
regeneration, in terms of motor and sensory recovery, and also by shortening the healing 
period avoiding regional muscular atrophy.7 
Even in PNS, nerve regeneration is still a very complex phenomenon that is far from being 
fully understood. However, with the advancement of tissue engineering and regenerative 
medicine it is expected that nerve grafts with a close similarity to native nerve tissue will be 
eventually developed and clinically applied.1 
The state-of-the-art presented in Chapter 2 was carried out in order to gather 
information about peripheral nerve regeneration, including the different strategies and 
approaches being studied and implemented when it comes to regenerate neurons that 
somehow have been injured. 
 
 
  
 
 
Chapter 2 
Literature review 
A literature review is presented in this section. Initially, the anatomy of the PNS will be 
addressed, followed by the explanation of the series of events that occurs after an injury. 
Most importantly, it will be addressed the requirements of a nerve graft, the strategies 
already implemented in the clinic and the approaches to be implemented in the future. 
 
2.1. The Peripheral Nervous System 
Neuroglial cells are quite different from nerve cells since they do not directly participate 
in the synaptic interactions and electrical signalling.9 These cells in both the PNS and the CNS 
have been regarded simply as the ‘glue’ that holds physically and metabolically the nervous 
system together. They are major players alongside the neurons of the PNS and the CNS.10 
Additionally, they provide a scaffold for some aspects of neural development and aid in 
recovery from neural injury.9 
All neurons in the PNS are in intimate physical contact with Schwann and satellite cells, 
regardless of whether they are myelinated or not, sensory or autonomic. All axons of the 
peripheral nerves are sheathed by rows of Schwann cells (Figure 1), in the form of either one 
Schwann cell to each axonal length or in Remak bundles, formed when an individual Schwann 
cell envelopes lengths of multiple unmyelinated axons.10,11 
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Figure 1 - Peripheral motor neuron showing the cell body, axon extension surrounded by a myelin 
sheath and the axons terminals (left). A cross section of the neuron shows the myelin sheath, composed 
of Schwann cells (right).12 
 
 
2.1.1. Schwann Cells 
Like the oligodendrocytes, Schwann cells are responsible for the production of the 
specialised, unique and complex spirals of myelin membrane. They can be categorized by 
their morphology, antigenic phenotype, biochemistry and anatomical location.9,10,11 
Myelin-forming Schwann cells have a profound impact in both the healthy and diseased 
nervous system, not only on axonal conduction but also on many properties of the axons 
themselves. Non-myelin-forming Schwann cells are in close contact with unmyelinated fibers, 
which are small-diameter axons of C fibers originating from sensory ganglia and axons from 
sympathetic neurons. These cells envelop a number of axonal lengths to form Remak bundles. 
It is becoming apparent that they are vital for the function and maintenance of unmyelinated 
axons and also necessary for pain sensation.5,10 
Satellite cells have a distinct partnership with the neuronal cell they ensheathe and are 
directly associated with the cell body rather than the axon of a neuron, so that each neuronal 
cell body in the dorsal root ganglia is surrounded by a cap of several satellite Schwann cells.6 
Some studies suggest that they have specific roles given their location and unique interaction 
with the sensory neuronal cell bodies they envelope.10 
Another feature of peripheral nerves is the presence of a continuous basal lamina tube 
that surrounds individual myelinated fibers and groups of nonmyelinated fibers for the entire 
length of the nerve. Also, there is the deposition of extracellular collagen in the endoneurial 
compartment.5 
The columns of Schwann cells, called bands of Büngner, are an indispensable pathway for 
directed axonal regeneration and provide an important permissive environment for axonal 
regeneration. Axons regenerate within these basal lamina tubes to reach motor or sensory 
  
 
targets. If regenerating axons do not grow within this environment, but through the 
endoneurial space within the connective tissue, they stop regenerating and do not reach their 
target.5 
 
The interdependence between Schwann cells and neurons underpins the functioning of 
the entire PNS. There is also a symbiotic relationship between them, since each one is 
dependent on the other for normal development, function and survival.13 On one hand, the 
axon controls the initiation of myelination, the number of myelin lamellae and the 
maintenance of the complex Schwann cell organization. On the other hand, Schwann cells 
regulate axonal diameter, neurofilaments spacing and phosphorylation, and the clustering of 
ion channels at the node of Ranvier in myelinated axons.10 
The PNS regenerative powers are in part due to intrinsic properties of Schwann cells that 
encourage spontaneous regeneration. PNS axonal regeneration occurs through the initiation 
of signalling cascades that activate Schwann cells to produce neurotrophic factors, cytokines, 
extracellular matrix (ECM) and adhesion molecules, which aid in regrowth of the injured 
nerve.14,15 This is in contrast to CNS neuroglia, in which astrocytes produce an hostile 
environment for axonal regeneration in response to injury.10 
 
Interactions between the PNS and other systems during development and maintenance 
should be considered. This becomes particularly important when it comes to the endocrine 
and immune systems which can have a considerable impact on the function of the PNS. 
Schwann cells play a crucial role in maintaining the equilibrium between the PNS and the 
immune system, being that their potential immunocompetence suggests that they can induce 
an immune response within the peripheral nerve.16 
 
2.1.2. Node of Ranvier 
The node of Ranvier is a segment as long as a millimetre of axon between adjacent 
Schwann cells and it is the site of action potential generation. The action potential of 
myelinated axons is generated at the relatively narrow node of Ranvier and skips from node 
to node, providing saltatory conduction.5 
 
2.1.3. Sodium Channels 
Sodium channels are the molecular batteries responsible for generating action potentials 
and they are present at the node of Ranvier in relatively high concentrations.5 
There are numerous sodium channel subtypes with different electrical properties. It has 
been established that the sodium channel subtype Nav 1.6 is the tetrodotoxin-sensitive, 
kinetically fast channel present at the normal node of Ranvier of peripheral nerve fibers.5 
Voltage-gated sodium channels (VGSCs) are members of the ion channel protein family 
and play an essential role in neuronal and non-neuronal function, being responsible for the 
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initiation and propagation of action potentials in excitable cells by allowing the influx of 
sodium ions.17 The very high density of VGSCs at the Ranvier node is important because 
synchronous activation of these channels provides substantial current to ensure the efficacy 
of activation of the next set of nodes and high-fidelity saltatory conduction. Moreover, for 
fast conducting regenerated myelinated axons to be functional, they must recapitulate 
appropriate nodal and myelin architecture.5 
The newly formed nodes of Ranvier of the regenerated axons expressed sodium channel 
subtype Nav 1.6, the normal predominant nodal sodium channel. This indicates that 
engraftment of exogenous Schwann cells into injured nerve can reconstitute myelin and 
appropriate sodium channel organization necessary for proper impulse conduction.5 In the 
sodium channel subtype Nav 1.6, tetrodotoxin binds to neurotoxin receptor within the outer 
vestibule of the VGSC and blocks the influx of sodium ions by occluding the outer pore of the 
channel. This binding inhibits the propagation of action potentials, thereby paralyzing nerve 
and muscle function.17 
 
2.2. Nerve Injury 
When peripheral nerve fibers are damaged the result is often axonal loss and 
demyelination followed by regeneration over short distances and remyelination under optimal 
conditions with the possibility of at least some functional recovery.1,5 The anatomy of axons 
goes through some changes after an injury and is characterized by primary degeneration with 
the distal portion of the severed cable being left non-functional, followed by a regenerative 
response of the proximal stump (Figure 2). However, in order to have an optimal recovery of 
nerve function, the outgrowing axons of the proximal portion of the nerve need to migrate 
their way through the distal one. This way, these axons will be guided back to their proper 
target innervation site.18 
 
Figure 2 - Schematic representation of the degenerative and regenerative events associated with 
peripheral nerve injury.2 
 
 
  
 
2.2.1. Wallerian Degeneration 
When peripheral nerves are transected, a series of molecular and cellular events are 
triggered throughout the distal stump of the transected nerves and within a small zone distal 
to the proximal stump. This is called the Wallerian degeneration and it results in the 
disintegration of axoplasmic microtubules and neurofilaments.1 Then, the axon diebacks a 
millimetre or two from the injury site and the distal segment degenerates. Within one day, 
most axons of the distal stump of transected nerves are reduced to granular and amorphous 
debris, which are then phagocytized by macrophages and monocytes. While the axon segment 
distal to the injury site degenerates, the Schwann cells proliferate typically within the basal 
lamina and form a longitudinal column of Schwann cells (band of Büngner).1,5 
 
2.2.2. Axonal Sprouting 
Roughly two days after the nerve injury, the proximal stump of the nerve gives rise to 
axonal sprouts that will extend either on the surface of Schwann cells or to the inner laminin-
rich surface of the basal lamina of the bands of Büngner. New axonal sprouts usually emanate 
from the nodes of Ranvier. In cases where both the proximal and distal nerve segments 
appose each other, regenerating axons may grow through these Schwann cell “scaffolds” and 
make contact with peripheral targets with the possibility of some functional recovery.1,5 
Under the influence of neurotrophic factors and ECM molecules produced by Schwann 
cells, several axonal sprouts are issued from a single regenerating fiber and grow within a 
single band of Büngner.  After making contact with the target, all but one of the sprouts 
dieback leaving a single fiber making contact with a peripheral target. The regenerated fiber 
is then myelinated by Schwann cells and signal conduction velocity is increased to 
appropriate levels. Usually, regenerated and remyelinated axons have shorter internodes, 
thinner myelin, and smaller axonal diameters, but nevertheless they can achieve rapid 
conduction.5 In humans, axon regeneration occurs at a rate of approximately 2–5 millimetres 
a day which means that significant injuries may take many months to heal.1 
However, sometimes the regenerating axon sprouts do not reach and elongate enough 
through the trophic distal Schwann cell tube. When this happens, they grow in a more 
random manner and form a neuroma, which is often the case after limb amputation. These 
sprouts present changes in the mechanosensitivity and chemosensitivity, which is associated 
to paresthesia and phantom limb.5 
 
2.3. Traditional Treatments 
Peripheral nerve regeneration is a process which depends on many factors, such as the 
large quantity and high speed of axonal outgrowth, the remyelination of axons by Schwann 
cells, and the maturity of regenerating nerve fibers. In several studies, the incorporation of 
support cells and/or growth factors has proven effective for modulating the above cellular 
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behaviours. This has been evidenced by a wide range of animal experiments, but it has not 
yet come to clinical use due to multiple barriers.1 
Several clinical interventions have been attempted for many years now in order to aid the 
repair of peripheral nerve injuries. During the 19th and 20th centuries a wide range of surgical 
techniques has been put into use for the management of peripheral nerve injuries.1 
The surgical techniques used to repair these kinds of injuries are classified into two 
general categories: manipulative nerve operations and bridge operations. The first includes 
direct neurorrhaphy, which is the surgical suturing of a divided nerve, and nerve transfers or 
neurotization and it is usually performed in the situation of no nerve tissue loss and possible 
approximation with minimal tension. Neurorrhaphy is only applicable to short nerve gaps 
because the fascicular coaptation may cause excessive tension over the suture line, which 
would inhibit nerve regeneration. Neurotization involves taking nerves or even nerve 
branches with redundant functions and transferring them to the target site in order to restore 
function of the severed nerves.1 
In cases where nerve loss is substantial, physicians often chose to interposition a nerve 
graft between the proximal and distal nerve stumps. The typical choice is to use an 
autologous nerve graft which is a functional but less important nerve segment self donated 
such as sural nerves, superficial cutaneous nerves or lateral and medial forearm nerves.19 
 
2.3.1. Autologous Nerve Grafts 
Autologous nerve grafting remains the gold standard technique, with an 80% recovery 
rate, to which other alternative treatments are compared. However, there are many 
drawbacks and disadvantages associated with this technique, such as limited availability of 
donor nerves, the need for a second surgery to obtain the donor nerve, donor site morbidity 
and secondary deformities, as well as mismatch between the injured nerve and the donor 
nerve.1 
Nerve grafts must fulfil some requirements when being placed in the injury site. The graft 
must not only cover the defect between the proximal and distal nerve stumps, it must also 
provide the optimal conditions and environment for axonal regeneration, such as Schwann 
cells, revascularization and endoneurial morphology.4 In addition, one of the major problems 
in surgical treatment is ends coaptation in the case of large loss of nerve tissue. Also, finding 
substitute implants that are not rejected by the organism is a requirement for the success of 
the technique.4 
Target reinnervation is one of the cellular events that predetermine functional recovery 
after peripheral nerve repair. When a nerve is transected with a damage of basal lamina 
tubes, axonal sprouts are not restrained to their original basal lamina tubes and axons 
become unable to grow faithfully along original pathways to their target regions. The 
mismatch of regenerated axons to their targets may contribute, at least in part, to 
unsatisfactory functional recovery after nerve grafting.1 
 
  
 
2.3.2. Allografts 
An alternative technique to autologous grafts is allografts. These are decellularized grafts 
that constitute an effective technique clinically adopted for peripheral nerve regeneration 
applications. Decellularized nerve allografts carry the benefit of preserving the basal 
lamina/ECM of the nerve, potentially leading to mechanical guidance of regenerating axons. 
They may also provide another potential technology to bridge critically sized defects.20 
AxoGen’s Avance® is an example of a decellularized allograft that has been used in the 
clinic to repair facial nerve and hand nerve defects.20,21 This allograft uses a protocol 
involving detergents and chondroitinases in the process of decellularization.18 However, in a 
study comparing different acellular allografts in a rat sciatic nerve defect it was found a 
superior performance in detergent-treated allografts than in AxoGen-treated and cold-
preserved allografts.22 When it comes to functionalization, none of these approved conduits 
have incorporated adhesive ECM proteins or neurotrophic factors.18 
This generation of conduits provides mainly physical guidance via conduit morphology in 
order to help to direct the damaged nerve to its target. The next generation will seek to 
increase nervous system function by using topographical and protein cues that interact with 
nervous tissue at the cellular level. These cues should also be tailored to the nerve and 
function of interest.18 
By developing biocompatible and anisotropic nerve guidance conduits (NGCs), tissue 
engineering offers clinical potential for peripheral nerve repair. The upcoming generation 
should be able to incorporate the use of neurotrophic factors, ECM proteins, surface 
micropatterning and favorable physical and mechanical properties.18 
 
2.4. Tissue Engineered Nerve Grafts 
In the last few decades, different types of biological or artificial grafts have been 
developed and investigated having as comparison autologous nerve grafts in terms of the 
outcomes of nerve regeneration and functional recovery.1 Also, the tissue engineering field 
has grown in the sense of offering great opportunities to investigators and surgeons to 
develop tissue engineered nerve grafts. These are usually composed of a physical scaffold 
with support cells and/or growth factors or other biomolecular components.1 
Tissue engineered nerve grafts, or neural scaffolds, have many purposes. They direct 
axons sprouting from the proximal to the distal nerve stump, they maintain adequate 
mechanical support for the regenerating nerve fibers, and provide a conduit channel for the 
diffusion of neurotrophic factors secreted by the damaged nerve stump and a conduit wall for 
the exchange of nutrients and waste products (Figure 3). Also, these neural scaffolds prevent 
the infiltration of fibrous scar tissue that hinders axonal regeneration and create an optimal 
microenvironment for nerve regeneration through the accumulation and release of exogenous 
and endogenous biochemical effects.1 
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The first generation of artificial nerve conduits clinically used was nonresorbable silicone 
tubes which covered the gap between the proximal and the distal stumps of a transected 
peripheral nerve. Clinical trials involved the resection of a rat sciatic nerve portion which 
was then encased by a cylindrical silicone chamber. However, these chambers were plagued 
by compression and often required secondary surgeries for removal.18,23 Ever since, a variety 
of different materials was approved for clinical use. 
Currently, there are some FDA-approved bioresorbable conduits being commercialized 
such as NeuroTube® (PGA), Neurolac® (PLCL) and NeuraGen® (type I collagen).18 
Despite their approval and success, some of these products present some issues which 
ultimately lead to their loss of efficacy. For example, Neurolac® initially showed promising 
results with regard to sensory recovery but later on it showed problems of biocompatibility, 
swelling, degradation rate and automutilation.24 NeuraGen® has also reported excellent 
clinical success for the surgical repair of brachial plexus birth injuries. However, it has been 
shown in a rat sciatic nerve model that processed nerve allografts behave significantly better 
than NeuraGen® in critically sized defects.25 Neurotube® represents a positive trend for short 
gaps. For digital nerve defects less than or equal to 3 centimeters, the conduit offered a 
higher percentage of patients with ‘‘excellent recovery,’’ though data was not statistically 
significant.18,26 Nevertheless, for critically sized defects in humans, which are characterized 
for being greater than 3 centimeters in length, NGCs are yet to approach the effectiveness of 
the gold standard, nerve autografts.18 
One of the purposes of Tissue Engineering nowadays is to associate NGCs made of 
biomaterials to other biological components that may have a decisive role in the final result 
of the peripheral nerve regeneration. The ultimate goal of this association is to improve 
nerve regeneration when it comes to motor and sensory recovery and to shorten the healing 
process avoiding regional muscular atrophy.27 
Using NGCs alone have been shown to be effective in terms of peripheral nerve 
regeneration but only until a certain point. When nerve gaps are over 30 millimeters, neural 
scaffolds only allow the bridging between the stumps. However, in order to have an effective 
regeneration, supporting cells and growth factors should be incorporated in the NGC.28 The 
cellular systems may include Schwann cells, mesenchymal stem cells and marrow stromal 
cells which may produce growth factors or ECM molecules or modulate the inflammatory 
process.28 These growth factors are important components of NGCs because they may 
enhance regeneration by promoting axonal outgrowth and neuronal survival.29 Besides cellular 
systems and growth factors, hydrogels may also be included in the NGCs architecture. They 
can be used as a physical barrier to protect the cells from hostile extrinsic factors or as a 
matrix to cell adhesion, growth and differentiation to further improve the secretion of 
therapeutic proteins by the cells.30 
When considering the use of these neural scaffolds in the clinic there are some 
requirements that they have to fulfil such as being easy to fabricate and sterilize, simple to 
implant in the body by microsurgical techniques, biocompatible and biodegradable. 
  
 
Biomechanical and surface properties are also major concerns. These requirements are 
mainly determined by the scaffold material and structure.1 
 
 
 
Figure 3 – NGC model showing the progression of events during peripheral nerve regeneration.12 
 
 
2.4.1. Requirements of an Ideal Scaffold 
2.4.1.1. Biocompatibility 
According to the original definition, biocompatibility is the ability to serve as a substrate 
that supports the appropriate cellular behaviours. These include the promotion of molecular 
and mechanical signalling systems to aid nerve regeneration, without eliciting any 
undesirable effects on neural cells and tissues and/or inducing undesirable local or systemic 
responses in the eventual host.31 
When in contact with blood, neural scaffolds must not induce hemolysis, destroy blood 
components or lead to coagulation and thrombus formation. The scaffold must also not have 
toxic effect on the surrounding tissues, neither teratogenicity nor gene mutation. On the 
other hand, these tissues should not induce corrosive effects or immune rejection on the 
scaffold. Finally, mechanical compatibility focuses on the matching of mechanical properties 
between the scaffold and the nerve tissue.1 
 
In order to analyse the biocompatibility of a new developed biomaterial for nerve 
regeneration, it is important to analyse the inflammatory response of the surrounding tissues 
before its application in nerve defects. For that purpose the evaluation should be a standard 
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and effective one. The International Organization for Standardization is a worldwide 
federation of international standard-setting bodies. ISO 10993-6:2007 was developed to 
specify test methods for the assessment of the local effects after implantation of 
biomaterials intended for use in medical devices.32 This section of ISO 10993 applies to 
materials that are solid and non-biodegradable, degradable and/or resorbable and non-solid 
such as porous materials, liquids, pastes and particulates. This part of ISO 10993 does not 
deal with systemic toxicity, carcinogenicity, teratogenicity or mutagenicity.33 The test 
specimen is implanted into a site and animal species appropriate for the evaluation of the 
biological safety of the material. These implantation tests are not intended to evaluate or 
determine the performance of the test specimen in terms of mechanical or functional 
loading. The local effects are evaluated by a comparison of the tissue response caused by a 
test specimen to that caused by control materials used in medical devices of which the 
clinical acceptability and biocompatibility characteristics have been established.32 The goal 
of these test methods is to characterize the history and evolution of the tissue response after 
implantation of a medical device/biomaterial including final integration or 
resorption/degradation of the material. Investigators must follow these guidelines when 
performing tests in animal models.27,30 
 
2.4.1.2. Biodegradability 
Ideally, a nerve scaffold should possess a controllable ability to degrade in vivo.1 
Therefore, non-degradable materials may not be advisable since they may become 
detrimental by virtue of toxicity or tendency to constrict nerve remodelling.1 Also, the 
degradation rate should be tuned to match the regeneration rate of the nerve.1 
 
2.4.1.3. Permeability 
Neural scaffolds construction must take into consideration the necessary gas and nutrient 
exchange and also the fluids exchange between the regeneration environment and 
surrounding tissues through pores in the conduit wall. The permeability of the scaffolds 
influences the formation of the fibrin matrix during the initial period of regeneration which 
leads to the conclusion that an increased permeability allows the mass transport and capillary 
in-growth, while maintaining a barrier to fibroblasts. Also, the permeability of NGCs may be 
needed for the viability of supportive cells.19,29 
There are different techniques through which NGCs can be made permeable, including by 
cutting holes into the wall, rolling of meshes, fibre spinning, adding salt or sugar crystals and 
injection-molding evaporation.29 
 
  
 
2.4.1.4. Biomechanical Properties 
Some biomechanical properties must be considered when designing neural scaffolds. One 
of them is the Young modulus, also known as elastic modulus, that should be similar to the 
one of the nerve tissues in order to resist in vivo physiological loads.1 
Some of the natural polymers used to make NGCs have a low mechanical strength. In 
order to fulfil the mechanical requirements, these polymers may be chemically modified and 
crosslinked with other structural components such as synthetic polymers.3 
During the nerve regeneration process, nerve scaffolds should have the capacity to 
withstand mechanical stress from neighbour tissues and maintain some elasticity and 
bendability without collapse or losing shape. They should also mechanically support the 
axonal sprouting between the injured nerve sprouts.19 Thus, a balance should be found 
between the hardness and the flexibility of the scaffold because scaffolds too stiff are easy 
to cause dislocation and scaffolds too flexible fail to support axonal regeneration.1 
 
2.4.1.5. Surface Properties 
The functionalization of the surface of neural scaffolds can influence the interactions 
between these structures and the nerve cells. Longitudinally oriented texture can be added 
to the surface, which has been shown to influence directional outgrowth of axons and 
uniform alignment of Schwann cells in vitro, resulting in better outcomes in nerve 
regeneration in vivo.34 
In addition, nanofibrous scaffolds have attracted research interest because they offer 
unique surface chemical properties such as high surface area favourable for cell attachment 
and growth and topographical signals favourable for directing cellular functions.35 
 
2.4.2. Natural Biomaterials in Neural Scaffolds 
2.4.2.1. Acellular Allogeneic or Xenogeneic Tissues 
As an alternative to autologous nerve grafts, other autologous non-nerve tissues, like 
muscles, veins, tendons and epineurial sheaths have been tested as structures to bridge 
peripheral nerve gaps. However, this approach showed limited success and still suffers from 
the problem of inadequate availability due to the autologous origin.36 
In contrast, allogeneic or xenogeneic tissues, which are either nerve tissues or non-nerve 
tissues, can be harvested from living donors, fresh corpses or animals, rather than from the 
patient, and thus they are used as the material for neural scaffolds with a potentially 
unlimited supply. Furthermore, amnion harvested from human placental tissues can be also 
employed as an allogeneic or xenogeneic tissue-derived material for preparing neural 
scaffolds.1 
 However, the nerve grafts made up of allogeneic or xenogeneic tissues are inevitably 
limited by immune responses of the host when they are implanted in vivo.37 At the time of 
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the implantation, immunosuppressive drugs must be administered to patients, which may 
leave them susceptible to infections and tumour formation.38 
When it comes to decellularization methods, freezing–thawing, sonication, and agitation 
are the common physical treatments, while chemical treatments are mainly performed by 
using various detergents.1 Since decellularization focuses on removal or destruction of the 
immunogenic cells and preservation of the ECM components that are essentially conserved 
between species, the resulting cell-free tissues can be used to prepare nerve grafts as a very 
appropriate alternative to autologous nerve grafts, especially in the repair of non-critical 
peripheral nerve gaps with a small length and diameter.39 
 
2.4.2.2. Naturally-derived Biopolymers 
Collagen, laminin and fibronectin are some of the insoluble components of the ECM that 
play an important role in the development and growth of axons.40 Other proteoglycans and 
glycosaminoglycans of the ECM can modulate neural activity and neuritis extension, providing 
either stimulatory or inhibitory effects.41 Thus, ECM components have become important 
candidate materials for neural scaffolds, being processed into lumen fillers of NGCs in the 
form of fibers, channels, porous sponges or hydrogels to serve as delivery vehicles for support 
cells, growth factors or drugs.1 
As previously mentioned, there are at the moment some FDA-approved, commercially 
available conduits which purpose is to regenerate peripheral nerves. One of these conduits is 
NeuraGen® which main constituent is type I collagen. However, gelatin derived from 
denatured collagen has also been investigated for a wide range of biomedical applications.42 
Gelatin was the first biodegradable material examined for preparing neural scaffolds, and 
gelatin-based neural scaffolds can be covalently incorporated with additional bioactive cues, 
which are gradually released during the scaffold biodegradation.43 
 
2.4.2.2.1. Alginate 
Commonly purified from seaweed, alginate is a naturally occurring copolymer of β-D-
mannuronate and α-L-guluronate and a biodegradable polysaccharide.4 This biopolymer has 
been implanted in sciatic nerve gaps in both rats and cats in the form of foam and the results 
showed that it could promote peripheral nerve regeneration.44 
In another study using cats which underwent severing of the right sciatic nerve, the gap 
was treated with both tubulation and non-tubulation repair. It was used a PGA mesh tube 
filled with alginate sponge. Successful axonal elongation and reinnervation in both the 
afferent and efferent systems were detected. Intracellular electrical activity was also 
recorded, which is directly indicative of continuity of the regenerated nerve and restoration 
of the spinal reflex circuit.45 
Several other studies were performed in order to evaluate the response of the nervous 
system after nerve severing and implantation of an alginate conduit. One of these studies 
suggested that by simply filling the nerve gap using an alginate sheet the nerve can be 
  
 
regenerated and erectile function may be restored.46 In another study, it was concluded that 
alginate gel presents a good biocompatibility for regenerating axon outgrowth and Schwann 
cell migration, which leads to the conclusion that alginate gel is a promising material for use 
as an implant for peripheral nerve regeneration.47 
 
2.4.2.2.2. Chitosan 
Chitin is the second most abundant polysaccharide found in nature and it can be isolated 
from the outer shell of crustaceans, insect exoskeletons, and fungal cell walls. As a 
biopolymer of N-acetyl-D-glucosamine monomeric units, chitin is extensively applied in a 
wide range of biomedical fields.1 
Chitosan is a natural and hydrophilic copolymer of D-glucosamine and N-acetyl-D-
glucosamine and it is obtained from full or partial N-deacetylation of chitin.1 It is also 
considered as a mucopolysaccharide with structural characteristics similar to glycosamines.48 
Since chitosan and glycosaminoglycans have very similar molecular structure, there are 
interactions between this biopolymer and ECM molecules including laminin, fibronectin and 
collagen.28 Its biodegradability, biocompatibility, non-antigenicity, notable affinity to 
proteins, promotion of cell adhesion and non-toxicity has made it possible to use chitosan in a 
number of biomedical applications, including wound dressings, drug delivery systems and 
space-filing implants.30,48 It has also seen its application in the tissue engineering field 
increase largely, serving as a candidate biomaterial for the development of neural scaffolds.1 
Being fragile in the dried form, chitosan can be chemically crosslinked or jointly used 
with other materials before scaffold fabrication.1 Chitosan matrices have low mechanical 
strength under physiological conditions and are unable to maintain a predefined shape after 
transplantation.28 For instance, their mechanical properties can be improved by modification 
with a silane agent named γ-glycidoxypropyltrimethoxysilane (GPTMS), which is one of the 
silane-coupling agents which has epoxy and methoxysilane groups. This modification, along 
with a freeze-drying technique, has been shown to produce chitosan type III membranes with 
90% porosity and successful improvement of rat sciatic nerve regeneration after axonotmesis. 
It was concluded that this material, apart from working as a simple mechanical scaffold, 
could also work as an inducer of nerve regeneration.28,49,50 
In another study, crystalline chitosan tubes with a tubular structure and an appropriate 
size for peripheral nerve reconstruction were obtained by removing calcium phosphate and 
proteins from crab tendons. Its mechanical strength however was low perpendicular to its 
longitudinal axis, resulting in the swelling of the tube surface wall which caused stenosis.51 
To improve the mechanical properties of a chitosan tube one can heat-press it into a 
triangular shape and modify it into apatite using an alternate soaking method.52 
Since it is considered a material with such good biomedical properties, several 
investigators have studied chitosan by testing it for peripheral nerve regeneration. It can be 
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fabricated using different techniques and it can be implanted with different forms, 
depending on the application site. 
 
2.4.2.3. Synthetic Materials 
Synthetic polymers constitute another class of promising biomaterials for fabricating 
neural scaffolds due to their tunable chemical and physical properties. However, these 
materials are incompatible with cell adhesion and tissue repair. Thus, they are often 
modified to render them ‘‘cell friendly.’’1 
Silicone tubes represent one of the first and most frequently used NGCs prepared with 
non-degradable synthetic materials because of its inert and elastic properties. Despite its 
non-degradability and no permeability to large molecules, silicone tubes provide an 
important model system for studying nerve regeneration under controlled conditions and 
have been applied in clinical trials to bridge short nerve gaps with some success.1 
Other non-degradable scaffolds have also been fabricated using acrylic polymer, 
polyethylene, and elastomer. Unfortunately, non-degradable materials are left in situ as 
foreign bodies after nerve regeneration, and therefore cause a chronic foreign body reaction 
with excessive scar tissue formation, ultimately inhibiting nerve functional recovery.1 
In order to overcome the restrictions imposed by the non-degradable materials, many 
experiments have been conducted using biodegradable synthetic polymers such as polylactic 
acid (PGA), poly(L-lactic acid) (PLLA), poly(L-lactic-co-glycolic acid) (PLGA) and poly-
caprolactone (PCL), which are used to prepare neural scaffolds. These degrade within a 
reasonable time span, and the degradation products are absorbed by the body accompanied 
with mild foreign body reactions.1,4 
Some of these synthetic materials properties can be modulated and tailored to match 
different application requirements and even to enable the entrapment of support cell or 
bioactive molecules for controlled delivery during nerve regeneration.1 For example, in one 
study, previously tested PLLA conduits were used to enhance the efficacy of peripheral nerve 
regeneration by incorporating them with allogeneic Schwann cells.53 
Of these materials, nerve guide implants made of collagen, PGA and poly-DL-lactide-co-
caprolactone (PLCL) are now approved by the FDA for human application and are already in 
clinical use.4 
 
2.5. Nerve Scaffold Functionalization 
As mentioned before, NGCs can be functionalized depending on the desired application. 
Focal application of neurotrophic factors and cell transplantation are two examples of 
functionalization.5 
 
  
 
2.5.1. Neurotrophic Factors 
Being a class of growth factors, neurotrophic factors can help to stimulate and control 
neurogenesis. They may be interchangeably termed as neurotrophins, but in its strict 
meaning, it only covers four structurally related factors: nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4/5. Neurotrophic 
factors have been widely investigated due to their role in nerve regeneration and their 
influence in neural development, survival, outgrowth and branching. 1,54 
Some neurotrophins such as the ciliary neurotrophic factor, the basic fibroblast growth 
factor and the BDNF are upregulated in Schwann cells in the degenerating axon segment. 
These neurotrophic factors can influence different functional classes of axons such as sensory 
and motor fibers, which makes essential to research and better understand the timing of 
expression and precise role of these factors in axonal regeneration, so this process can be 
enhanced.5 
Understanding the changes that occur in growth factor expression in the injured 
peripheral nerve might indicate suitable pharmacological therapies for repair and 
enhancement of muscle reinnervation.55 The NGF was the first neurotrophic factor to be 
identified and although it exists only in low levels in the healthy nerve, it shows rapid 
increases in expression after nerve injury. Satellite glial cells surrounding the dorsal root 
ganglion have been shown to up-regulate levels of NGF after axotomy, which contributes to 
the induction of sympathetic nerve sprouting after injury. Schwann cells at the injury site can 
also rapidly up-regulate NGF levels, possibly to compensate for the loss of supply from the 
nerve itself.55 The BDNF has its origin in inflammatory cells and it has been demonstrated 
that it mediates neuroprotective effects. This is an important factor for motor neurons, 
influencing the expression of cholinergic genes and promoting cell survival in culture.16 
However, in vivo responses to neurotrophic factors can vary due to the method of their 
delivering. Therefore, the development and use of controlled delivery devices are required 
for the study of complex systems.54 
 
2.5.2. Support Cells 
Adding supportive cells to NGCs are one of the most extensively investigated 
modifications to the single-lumen nerve tube. One of the cell types is Schwann cells which 
are known to possibly enhance nerve regeneration by different mechanisms.29 Schwann cells 
are a highly preferred substrate for axon migration and they also express neural cell adhesion 
molecules. Apart from Schwann cells, stem cells have been isolated from different regions of 
the human body and have been studied as candidates of support cells for nerve regeneration 
applications.15 
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2.5.2.1. Mesenchymal Stem Cells 
Stem cells are a very unique cell type and have special characteristics that allow them to 
fulfil some functions that other cells cannot. Cell transplantation of mesenchymal stem cells 
(MSCs), embryonic stem cells (ESCs) and marrow stromal cells has been proposed as a method 
of improving peripheral nerve regeneration.7 The success of their implantation depend on the 
fact that they can grow and divide indefinitely, can differentiate into specialized cells and be 
delivered to the site of lesion associated to biomaterials.30 
Besides cell-based therapies for various diseases, MSCs have become one of the most 
interesting targets for tissue regeneration including peripheral nerves.1 According to the 
International Society of Cell Therapy, MSCs are progenitor cells for the mesenchymal 
lineages, plastic adherent and also capable of self-renewal with sustained proliferation in 
vitro and can differentiate into multiple mesodermal cells, including neuron-like cells.7,27,30 It 
is also possible for them to differentiate into non-mesenchymal lineages, including 
myelinating cells of the PNS. One of the advantages of using these cells is their high plasticity 
and low immunogenicity, which makes them a desirable form of cell therapy for the injured 
nervous system without requiring the use of immunosuppressive drugs during the treatments.7 
MSCs have been isolated from various sources including skin, hair follicles, periosteum, 
amniotic fluid, umbilical cord, dental pulp and adipose tissue.7 They can be harvested after 
birth, cryogenically stored, thawed and expanded for therapeutic uses.30 Stem cells derived 
from extra-embryonic tissues are a good alternative to those derived from the umbilical cord, 
which have associated to them a painful aspiration.27 MSCs isolated from the human umbilical 
cord matrix, also known as Wharton’s jelly, are originated from inner cell mass of blastocyst 
and present positive effects in nerve and skeletal muscle regeneration being that there are 
no ethical or technical issues.28,30 Comparing with ESCs, MSCs have shorter population 
doubling time, they can be easily cultured in plastic flasks and are well tolerated by the 
immune system which means that their transplantation into non-immune suppressed animals 
does not induce acute rejection. Also, they can differentiate into adipocytes, osteoblasts, 
chondrocytes, cardiomyocites, neurons, and glia.27,30 
Recently, stem cells derived from dental pulp (DPSCs) received growing attention due to 
common characteristics with other mesenchymal stem cells beside their ease of obtainment 
and propagation, since they can be isolated with non-invasive procedures. The use of DPSCs 
in research and therapy is therefore not considered to be controversial.56,57 These cells can 
be successfully cryopreserved with good viability and function upon thawing, suggesting that 
it may be feasible to bank them and/or dental tissue.58 Studies show that DPSCs could 
differentiate into many types of lineages, such as odontoblasts, osteoblasts, adipocytes, 
skeletal and smooth muscle cells, elastic cartilage cells, endothelial and neural cells both in 
vivo and in vitro conditions.56 
There are two main techniques to implant cultured cells into defective nerves which have 
been subjected to either neurotmesis or axonotmesis. In the first case, the neural scaffold is 
interposed between the nerve stumps, being the cells injected directly into the scaffold. In 
  
 
the axonotmesis case, the neural scaffold is placed around the crush injury. The cellular 
system can also be pre-added to the scaffold via injection or co-culture, being later 
implanted in the injured nerve.27 
Contrarily to what happens with the fabrication of the neural scaffolds, the quality of 
cells varies within patients and it depends on the individual tissue characteristics, on the 
transport conditions and time of the samples to the laboratory and on the processing and 
cryopreservation techniques.27 
 
2.6. Additional approaches 
Besides all the strategies to regenerate peripheral nerves that are being studied, some 
others might be useful to complement or even improve them. 
In some situations it may be of interest to use drug delivery systems made up of 
degradable biomaterials, which may become a helpful strategy for controlled release of 
growth factors.1 Furthermore, a study has shown that the ability of an artificial nerve guide 
to deliver growth factors and Schwann cells is important for enhancing functional recovery.55 
In these cases, degradable grafts are advantageous because, as they degrade, they will 
release growth or trophic factors trapped in or adsorbed to the polymer.4 
In addition, electric stimulation has been shown to enhance nerve regeneration, and 
thereby construction of tissue engineered nerve grafts with electrically conductible polymers 
or by nanotechniques may represent some new avenues worthy of intensive research.1 
Transplantation of Schwann cells could assist the regenerative process in a way that they 
can be added directly to the lumen of a biodegradable artificial nerve graft.12 Because they 
can be grown relatively easily in culture, they can be manipulated to enhance their 
regenerative properties or to act as vehicles for gene therapy.10 Schwann cells suspended in 
gelatin within the lumen of a PGA acid conduit have been shown to support nerve 
regeneration over a 30-mm gap in the peroneal nerve in rabbits.12 
Hydrogels are water-swollen crosslinked polymer networks that often present 
characteristics such as tissue-like elasticity and mechanical strength.59 They are used in 
clinical and experimental practice in various applications, including tissue engineering. 
Hydrogels are usually considered highly biocompatible due to their high water content and 
also to the physiochemical similarity with the native ECM. Dextrin, a starch-based natural 
polymer, has a great potential for the development of hydrogels owing to its proven clinical 
tolerability and efficient absorption. This low molecular weight polymer was used to develop 
a resorbable hydrogel without using any chemical initiators. Dextrin was oxidized with sodium 
periodate and after testing it showed good mechanical properties and biocompatibility. It 
presents a three-dimensional network with a continuous porous structure which can be used 
to fill the lumen of NGCs.60,61 
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Chapter 3 
Preliminary Experimental Work 
This section outlines the preliminary work performed as a preparation for the dissertation 
experimental work and it was a task developed in a financed project of the laboratory - QREN 
I&DT Cluster in Development of Products for Regenerative Medicine and Cell Therapies – 
Projects Biomat & Cell QREN 2008/1372, co-financed by the European Community FEDER fund 
through ON2 - O Novo Norte – North Portugal Regional Operational Program 2007-2013, by 
project FCT "Hybrid Nanostructured Hydrogels: Bone regeneration using Multifunctional 
injectable Hydrogels - Rebone" – ENMED/0002/2010 from Fundação para a Ciência e 
Tecnologia (FCT). Also these results were obtained in collaboration with other researchers of 
the referred project. 
 
3.1 Culture of Mesenchymal Stem Cells 
The culture procedure of one of the cellular systems – MSCs from the Wharton’s jelly of 
the umbilical cord - has been already tested associated to several biomaterials in the 
axonotmesis and neurotmesis injury model, and by me for the proposed thesis.27,62 
 
  
 
  
Figure 4 - MSCs from Wharton’s jelly exhibiting a mesenchymal-like shape with a flat polygonal 
morphology (left). After 72h of culture in neurogenic medium the cells became exceedingly long and 
there is a formation of typical neuroglial-like cells with multibranches (right) (x100). 
 
 
Figure 4 represents the morphology of MSCs derived from Wharton’s jelly in culture. MSCs 
were expanded and exhibited a mesenchymal-like shape with a flat and polygonal 
morphology. During expansion the cells became long spindle-shaped and colonized the whole 
culturing surface. 
Before in vivo testing, cells were also characterized by flow cytometry analysis for a 
comprehensive panel of markers, such as platelet endothelial cell adhesion molecule – 1 
(PECAM-1, CD31), homing cell adhesion molecule (HCAM, CD44), CD45, and Endoglin (CD105). 
The MSCs phenotype was confirmed and also the karyotype analysis was performed to confirm 
the somatic and sexual chromosome stability. 
 
3.2 Animal Model 
In this manuscript, it is briefly resumed the results already obtained with the evaluation 
of the biocompatibility of the cellular system and a hydrogel that can be used as a vehicle in 
axonotmesis and neurotmesis injuries reconstruction and that might improve the healing 
process. 
Concerning the test performed in rats, for the in vivo subcutaneous implantation a total 
of 34 rodents were used. The adult male Sasco Sprague Dawley rats (Charles River 
Laboratories, Barcelona, Spain) weighed from 250 to 300 g and were randomly divided into 
groups of three animals each. Two animals were housed per cage in approved ones (Makrolon 
Type 4, Tecniplast, VA, Italy), in a room with controlled temperature and humidity with light 
and dark cycles every 12 hours. The animals were allowed normal cage activities under 
standard laboratory conditions and were fed with standard chow and water ad libitum. 
All the animal testing procedures were in conformity with the Directive 2010/63/EU of 
the European Parliament and with the approval of the Veterinary Authorities of Portugal in 
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accordance with the European Communities Council Directive of November 1986 
(86/609/EEC). Humane endpoints were followed in accordance to the OECD Guidance 
Document on the Recognition, Assessment and Use of Clinical Signs as Humane Endpoints for 
Experimental Animals Used in Safety Evaluation (2000). Adequate measures were taken to 
minimize pain and discomfort considering humane endpoints for animal suffering and distress. 
Animals were housed for two weeks before entering the experiment. 
 
3.3 Experimental Procedure 
Anesthesia was achieved with an intraperitoneal injection of a pre-mixed solution 
consisting of 100 mg/kg of body weight of ketamine (Imalgène 1000®) and 200 mg/kg of body 
weight of xylazyne (Rompun®). Hair from the dorsal area of the animals was clipped and the 
skin scrubbed in a routine fashion with an iodopovodone 10% solution (Betadine®) and three 
long incisions of about 1,5-2 cm were made. Incision 1 was left-cranial, incision 2 was mid-
right and incision 3 was left-caudal. To rat number three of each experimental group was 
performed a fourth type of incision, which was near the tail, corresponding to sham sample. 
After blunt dissection towards the ventral aspect of the body, the biomaterials were 
deposited subcutaneously. Skin and subcutaneous tissues were closed with a simple-
interrupted suture of a non-absorbable filament (Synthofil®, Ethicon). After the experimental 
period, samples were collected on days 3 and 15. Afterwards, the rats were euthanized by 
lethal intracardiac injection of 5% sodium pentobarbital (Euthasil®). The implant area was 
then excised, with limits large enough to also retrieve sufficient unaffected surrounding 
tissue. 
As described before, dextrin hydrogel was obtained through oxidation by sodium 
periodate and then cross-linked with adipic acid dihydrazide. The sterilization of dextrin 
hydrogels was performed by gamma radiation (room temperature; 25 kGy). Immediately 
before implantation, the hydrogel was crosslinked and allowed complete full gelation inside a 
syringe for administration. The hydrogel was developed by the research group from 
Universidade do Minho, supervised by Prof. Miguel Gama and included in the PhD thesis of Dr. 
Dina Silva. 
 
3.4 Samples analysis 
After collecting the samples, a macroscopic evaluation was performed followed by 
photographical records. Each implant site was examined for alterations in the normal 
structures, the nature and extent of any tissue reaction such as hematoma, edema, 
encapsulation and/or additional gross findings and for the presence, form and location of 
implant including possible remnants of degradable materials. Whenever possible, lymph 
nodes from the rat were also collected in order to assess for material migration and other 
abnormalities. However, collecting the lymph nodes might prove very difficult when no 
enlargement is present, due to the size of the test animals. 
  
 
Macroscopic evaluation of the samples allowed the observation that all the tissue 
surrounding the implant zone did not exhibit signs of abnormalities or infection. Furthermore, 
there were no signs of fibrous capsule formation around the materials implanted. Hydrogel 
samples were still possible to identify after three days post-implantation as seen in Figure 5. 
This result indicates that the hydrogel degradation rate in vivo is lower than in vitro. 
 
 
Figure 5 - Hydrogel after 3 days. 
 
For the sample which contained the hydrogel and MSCs, the quantity of hydrogel that 
remained in the implant site was smaller when compared with the hydrogel alone (Figure 6). 
This may be explained by the dilution that occurred during the incorporation of MSCs in the 
hydrogel mixture, which affects the crosslinking reaction. 
 
  
Figure 6 - MSCs and hydrogel after 3 days. 
 
Sample collection after 15 days showed that no hydrogel sample was present in the 
implant site, as seen in Figure 7. 
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Figure 7 - Hydrogel after 15 days. 
 
In cases when animals presented signs of ill health or reactions to the implant, a gross 
necropsy and collection of other organs were indicated to assess systemic toxicity. All the 
observed organs (kidney, liver, spleen and lungs) from these experimental animals presented 
normal characteristics and, despite being subjected to proper histological processing, they 
have not yet been evaluated. 
 
3.5 Histological study 
To perform the microscopic evaluation of the tissue response, two kinds of scoring 
systems have been reported and are classified as quantitative and semi-quantitatively scoring 
systems. In the case of this study, a semi-quantitative system was adopted, following the 
suggestion on the Annex E of the ISSO 10993-6 standard. Such system was preferred over 
more recent references as these have not yet been validated for all of the test species and 
evaluated tissues the work group routinely deals with. 
The collected samples were fixed using 10% buffered formalin and processed for routine 
histology. The first important microscopic aspect observed was that the lesion and the traces 
of the implants were located below the muscle layer rather than at the subcutaneous area. 
This may be due to the movement of the animal, which made the implant to shift to the 
lower layer. 
 
Table 1 - Histological scoring. 
 
TEST SAMPLE 3 days SCORE (TEST-SHAM) CLASSIFICATION 
Hydrogel 
Hydrogel + MSCs 
4,05 
2,45 
SLIGHT IRRITANT 
NON-IRRITANT 
TEST SAMPLE 15 days 
Hydrogel 
SCORE (TEST-SHAM) 
2,14 
CLASSIFICATION 
NON-IRRITANT 
Hydrogel + MSCs 0 NON-IRRITANT 
  
 
 
3.6 Final considerations 
After the analysis of the histological results, it was possible to assess various key 
parameters to determine the local effect of the implanted material such as the extent of 
fibrosis/fibrous capsule and inflammation, the degeneration, the number and distribution of 
the inflammatory cell types, such as polymorph nuclear neutrophilic leucocytes, 
lymphocytes, plasma cells, eosinophils, macrophages and multinucleated cells, the presence, 
extent and type of necrosis, the vascularization, fatty infiltration, granuloma and bone 
formation and fragmentation and/or debris presence, form and location of remnants of 
degraded material. 
Based on the preliminary results obtained, some provisory conclusion can be pointed out. 
The dextrin hydrogel seemed to elicit only a slightly irritant acute response, which tends to 
evolve favorably. Therefore, this hydrogel appears to be a suitable vehicle for implantation. 
Also, the inclusion of MSCs to the system seemed to induce a positive effect on the 
progression of the inflammatory response. The acute tissue response appeared to be more 
controlled and to be evolving faster towards the confinement of the lesion within a fibrous 
capsule. 
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Chapter 4 
Experimental Work 
This section outlines all the experimental work performed and respective display and 
interpretation of results. 
The goals established for this work were to prepare chitosan guide tubes crosslinked with 
GPTMS, to mechanically and structurally characterize them, and finally to implant them in a 
group of animals. This would allow to compare the obtained results with others already 
described and published and to assess if improvements were achieved. 
 
4.1 Materials and Methods 
4.1.1. Preparation of the guide tubes 
Chitosan (degree of deacetylation: >75%; Sigma-Aldrich®, USA) was dissolved at room 
temperature in a 0.25 M acetic acid solution in order to attain a concentration of 2% (w/v). 
At the same time, GPTMS (Sigma-Aldrich®, USA) was also dissolved for 1 h at room 
temperature in a 0.25 M acetic acid solution, resulting in a concentration of 27.7% (w/v). In 
order to induce the crosslinking, the GPTMS solution was added to the chitosan solution to 
obtain a molar ratio of 1:0.5 (chitosan:GPTMS). After stirring at room temperature for 1 h, 
the resultant chitosan-GPTMS solution was poured into teflon molds which were kept at -20oC 
for 24 h. The frozen guide tubes were subsequently transferred to a freeze-dryer (FreeZone 
Plus 2.5 Freeze Dry System, Labconco®, USA) in which the samples were lyophilized for 48 h 
to complete dryness. These guide tubes were then soaked in a 0.1 M NaOH aqueous solution 
to neutralize remaining residues of acetic acid, carefully washed with distilled water, and 
lyophilized once again for another 48 h. In the end of the preparation, the guide tubes were 
1.6 cm long, had an internal diameter of 3 mm and a wall thickness of 1.5 mm. Finally, the 
guide tubes were stored until being used for implantation and other assays.8,49,62,63 
PLGA guide tubes were also prepared in order to make a comparison between them and 
chitosan-GPTMS guide tubes. PLGA copolymers with a ratio of 90(PLA):10(PLG) were obtained 
  
 
from their cyclic dimmers, DL-lactide and glycolide. Synthetic nonwoven constructs were 
used to prepare the guide tubes. These materials are extremely flexible, biologically safe, 
and are able to sustain the compressive forces due to body movement after implantation.64,65 
 
 
Figure 8 – Chitosan-GPTMS (left) and PLGA (right) guide tubes before implantation. 
 
 
4.1.2. Structural characterization of the guide tubes 
4.1.2.1. Scanning Electron Microscopy (SEM) 
The morphology and microstructure of the chitosan-GPTMS guide tubes were observed 
under a scanning electron microscope (Quanta 650, FEI™, USA) with an accelerating voltage 
of 5 kV. Previous to observation, the samples were coated with a thin gold layer using a 
sputter coating (Polaron SC502). 
 
4.1.2.2. Fourier Transform Infrared (FTIR) Spectroscopy 
Chitosan-GPTMS guide tubes and chitosan powder were characterized by FTIR 
spectroscopy. Infrared spectra were obtained by an infrared spectrometer (Jasco® 4100). 64 
scans were performed with a resolution of 4 cm-1. 
 
4.1.2.3. Water uptake assay 
In order to evaluate the water uptake of the guide tubes, the samples were soaked in a 
phosphate-buffered saline (PBS) solution at pH 7.4. Samples were weighed in their dry form 
and then kept at 37ºC. The ratio between their masses and the volume of PBS had to be at 
least of 1:10 (w/v). After each time point the samples were left to dry on top of a filter 
paper and then weighed and put in a new solution of PBS. This way the water uptake was 
obtained, i.e., the amount of water adsorbed according to Equation 1, where Wd and Ww 
stand for the weights of the guide tubes before and after being soaked in PBS, respectively.48 
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4.1.2.4. Determination of the degree of crosslinking 
The degree of crosslinking of the guide tubes was evaluated by ninhydrin (NHN) assay, 
which determines the percentage of free amino groups (NH2) remaining in the guide tubes 
after crosslinking.  At first, a solution of citric acid, NaOH 1.0 M and SnCl2·2H2O was 
prepared and mixed for 45 minutes with a solution of ninhydrin dissolved in ethylene glycol 
monomethyl ether. Then, a sample was heated to 100oC in a water bath with 1 mL of 
ninhydrin solution for 20 minutes. The solution was cooled down to room temperature, 
diluted with 50% isopropanol, and then its optical absorbance was measured at 570 nm with a 
spectrophotometer (UV-2501PC, Shimadzu). The optical absorbance of the chitosan powder 
was also measured at 570 nm. The amount of free amino groups in the test sample is 
proportional to the optical absorbance of the solution. The concentration of free amino 
groups in the sample was determined from a calibration curve of glycine concentration vs 
absorbance. The concentration measured was divided by sample weight, and multiplied by 
the sample molecular weight to obtain the mole NH2/mole sample. The degree of crosslinking 
of the sample was then calculated according to Equation 2, where NHN reactive aminefresh is 
the mole fraction of free NH2 in non-crosslinked samples and NHN reactive aminefixed is the 
mole fraction of free NH2 remaining in crosslinked samples.
66 
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4.1.2.5. Mechanical assay 
In order to evaluate the mechanical behaviour of the guide tubes, stress-strain curves 
were recorded using dry and hydrated samples. The latter were kept for 2 h in ultra pure 
water. Strip-shaped membranes were stretched using a crosshead speed of 1 mm.min-1 (AG-IS 
500N, Autograph, Shimadzu). Five samples for each condition were tested. The Young 
modulus (E) was calculated from the stress at break and the strain at break of the guide 
tubes. 
 
 
 
 
 
  
 
 
Figure 9 - Chitosan-GPTMS membrane assembled in the universal testing machine. 
 
 
4.1.3. In vivo Testing 
4.1.3.1. Ethics and Regulation 
All the animal testing procedures were in conformity with the Directive 2010/63/EU of 
the European Parliament and with the approval of the Veterinary Authorities of Portugal in 
accordance with the European Communities Council Directive of November 1986 
(86/609/EEC). Humane end points were followed in accordance to the OECD Guidance 
Document on the Recognition, Assessment and Use of Clinical Signs as Humane Endpoints for 
Experimental Animals Used in Safety Evaluation (2000). Adequate measures were taken to 
minimize pain and discomfort taking into account human endpoints for animal suffering and 
distress. Animals were housed for two weeks before entering the experiment. 
 
4.1.3.2. Microsurgical Procedure 
Adult male Sasco Sprague Dawley rats (Charles River Laboratories, Barcelona, Spain) 
weighing between 250 and 300 g were used for the in vivo tests and randomly divided in 
groups of 6 animals each for control groups (Gap, End-to-end, Graft, PLGA and Chitosan-
GPTMS (Ch-GPTMS) groups). The Ch-GPTMS group with a neurotmesis injury surgically 
reconstructed with a chitosan guide tube was only composed by 4 animals. All animals were 
housed in a temperature and humidity controlled room with 12-12 h light/dark cycles and 
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were allowed normal cage activities under standard laboratory conditions. The animals were 
fed with standard chow and water ad libitum. 
For surgery, the animals were placed prone under sterile conditions and the skin from the 
clipped lateral right thigh was scrubbed in a routine fashion with antiseptic solution. Rats 
were put under deep anaesthesia (ketamine 90 mg/kg; xylazine 12.5 mg/kg, atropine 0.25 
mg/kg, intraperitoneal), after which the right sciatic nerve was exposed through a skin 
incision extending from the greater trochanter to the mid-thigh distally followed by a muscle 
splitting incision. After nerve mobilization, all animals were subjected to a transection injury 
(neurotmesis) immediately above the terminal nerve ramification using straight microsurgical 
scissors. Then, the proximal and distal nerve stumps were inserted into the guide tube which 
was held in place with 2 epineurial sutures using 7/0 monofilament nylon. Opposite leg and 
sciatic nerve were left intact in all animals (Ch-GPTMS group – Group 6). A group of 6 animals 
was used as control without any sciatic nerve injury (Group 1 – Control). In Group 2 the 
injured nerve was left without any repair intervention (Group 2 - Gap). In Group 3, 
immediate cooptation with 7/0 monofilament nylon epineurial sutures of the 2 transected 
nerve endings was performed (Group 3 – End-to-End). In Group 4 (Group 4 - Graft), the sciatic 
nerve was transected immediately above the terminal nerve ramification and at a 10 mm 
distal point. The nerve graft obtained, with a length of 10 mm was inverted 180o and sutured 
with 7/0 monofilament nylon. Opposite leg and sciatic nerve were left intact in all groups and 
served as control for normal nerves. Finally, in Group 5 (Group 5 – PLGA), after transection of 
the sciatic nerve, both the proximal and distal nerve stumps were inserted 3 mm into a PLGA 
guide tube and held in place with 2 epineurial sutures using 7/0 monofilament nylon. 
 
 
Figure 10 – Rat sciatic nerve before (A) and after neurotmesis (B), followed by the nerve reconstruction 
with a chitosan-GPTMS guide tube (C and D). 
  
 
 
4.1.3.3. Functional Assessment 
All animals were tested pre-operatively (week 0), at week 1 and every two weeks after 
the surgery, for a total period of follow-up of 20 weeks. Animals were gently handled and 
tested in a quiet environment to minimize stress levels. 
 
4.1.3.3.1. Evaluation of Motor Performance and Nociceptive Function 
Motor performance and nociceptive function were evaluated by measuring extensor 
postural thrust (EPT) and withdrawal reflex latency (WRL), respectively. 
The EPT test was proposed as a part of the neurological recovery evaluation in the rat 
after sciatic nerve injury.67 For this test the entire body of the rat, except for the hindlimbs, 
was wrapped in a surgical towel. Supporting the animal by the thorax and lowering the 
affected hindlimb towards the platform of a digital balance, the EPT was elicited. As the 
animal is lowered to the platform, it extends the hindlimb, anticipating the contact made by 
the distal metatarsus and digits. The force applied in grams by the rat towards the digital 
balance was recorded. The same procedure was applied to the contra-lateral, unaffected 
limb. For this test, both limbs were tested 3 times and the 3 values were averaged in order to 
obtain a final result. The normal EPT (NEPT), regarding the unaffected limb, and the 
experimental EPT (EEPT) values were incorporated into Equation 3 to derive the percentage 
of functional deficit.64,68,69 
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The hotplate test previously described in the literature was modified to assess the 
nociceptive withdrawal reflex.70 Wrapped in a surgical towel, the animal was positioned so it 
would stand with the affected hind paw on a plate at 56oC. WRL is defined as the time 
elapsed from the onset of hotplate contact to withdrawal of the hind paw and measured with 
a stopwatch. Normal animals withdraw their paws from the hotplate within 4.3 seconds or 
less.49,64,71 Both the affected and normal limbs were tested 3 times and the three latencies 
were averaged to obtain a final result. If there was no paw withdrawal after 12 seconds, the 
heat stimulus would be ceased in order to prevent tissue damage, and the animal would be 
assigned the maximal WRL of 12 seconds. 
 
4.1.3.3.2. Sciatic functional index and static sciatic index 
For sciatic functional index (SFI), the animals were tested in a confined walkway 
measuring 42 cm long and 8.2 cm wide, with a dark shelter at the end.64,72,65 White paper 
sheets were placed on the floor of the walkway. The hind paws of the rats were pressed 
down onto a finger paint-soaked sponge, after which they were put to walk down the corridor 
leaving its hind footprints on the paper. Several measurements were taken from the 
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footprints: (i) distance from the heel to the third toe, the print length (PL); (ii) distance from 
the first to the fifth toe, the toe spread (TS); and (iii) distance from the second to the fourth 
toe, the intermediary toe spread (ITS). For both dynamic (SFI) and static assessment (SSI), all 
measurements were taken from the experimental (E) and normal (N) hindlimbs. Prints for 
measurements were chosen at the time of walking based on clarity and completeness at a 
point when the rat was walking briskly. The mean distances of the three measurements were 
used to calculate the following factors (dynamic and static): 
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SFI was calculated as described in the literature according to Equation 7 and averaged 
values were used.73 
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For the SSI evaluation, only the parameters TS and ITS were measured.74 
 
                                           (8) 
 
For both SFI and SSI, an index score of 0 is considered normal and an index of -100 
indicates total impairment. When no footprints were measurable, an index score of -100 was 
given.75 
 
4.1.3.4. Sciatic nerve stereology and histological analysis 
A histomorphometric analysis was performed for the present case study. Nerve samples 
obtained from un-operated controls were processed for quantitative morphometry of 
myelinated nerve fibers.76 Fixation was carried out using 2.5% purified glutaraldehyde and 
0.5% saccarose in 0.1 M Sorensen phosphate buffer for 6 to 8 h and resin embedding was 
obtained following Glauerts' procedure.77 Series of about 50 semi-thin transverse sections (2 
µm thick) were cut using a Leica Ultracut UCT ultramicrotome (Leica Microsystems, Wetzlar, 
Germany) starting from the distal end of the specimen and stained by Toluidine blue. 
Stereology was carried out on one section, randomly selected each of these series, using a 
DM4000B microscope equipped with a DFC320 digital camera and an IM50 image manager 
system (Leica Microsystems, Wetzlar, Germany). Systematic random sampling and D-dissector 
  
 
were adopted using a protocol previously described.78,79 Fiber density and total number were 
estimated together with fiber and axon diameter and myelin thickness. 
 
4.1.4 Statistical analysis 
Differences in motor deficit and nociception recoveries and axon counts between 
experimental groups were analyzed by two-way mixed factorial ANOVA, with experimental 
groups as between subjects factor, and time of recovery as the within subjects factor. 
Whenever a significant main effect was found for the between subjects factor, pairwise 
comparisons were carried out by applying the Turkey’s HSD post hoc test. The Mauchly’s test 
of sphericity was used to assess sphericity, and in cases significant deviations from the later 
existed, a correction of the degrees of freedom was used by means of the more conservative 
Grenhouse-Geiser’s Epsilon. T tests were used for comparisons between experimental groups 
at week 1 post-surgery, with Bonferroni adjustment for multiple comparisons. All statistical 
analysis were carried out using the SPSS software package (SPSS, Chicago) and statistical 
significance was accepted at P < 0.05. The experimental Ch-GPTMS group was not included in 
this preliminary statistical analysis. It will be included in the end of the 20 week recovery 
period. 
 
 
4.2 Results 
4.2.1 SEM 
Figure 11 shows the microstructure of the chitosan-GPTMS guide tubes, being that Figure 
11(B) is a close-up of Figure 11(A). The images clearly show that the chitosan-GPTMS guide 
tubes are highly porous, which is in accordance to previous studies where investigators 
produced chitosan-GPTMS membranes also highly porous. In these studies, it was 
demonstrated that the membranes had a porosity of ~90% and that pores were 110 µm.8 
 
 
Figure 11 - SEM images of the chitosan-GPTMS guide tubes. 
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4.2.2 FTIR 
The FTIR spectra of chitosan-GPTMS guide tubes and chitosan powder is represented in 
Figure 12(A) and Figure 12(B), respectively. The GPTMS monomer has three characteristic 
peaks at 2840 cm-1, 1192 cm-1 and 914 cm-1.80 The bands around 1650 and 1565 cm-1 are 
characteristic of chitosan and are denoted as amide bands I and II, respectively.81,82 In the 
chitosan spectrum, the wide peak in the 3500-3300 cm-1 region is attributed to hydrogen-
bonded O-H stretching vibration. The peak for asymmetric stretch of C-O-C is found at around 
1150 cm-1 and the peak at 1317 cm-1 corresponds to the C-N stretching vibration of type I 
amine.83 The reaction between amine groups in chitosan and oxirane groups in GPTMS can be 
noticed in the transmittance band at 1550 cm-1.84 
 
 
Figure 12 - FTIR spectrum of chitosan-GPTMS guide tubes (A) and chitosan powder (B). 
 
 
4.2.3 Water uptake 
Figure 13 shows the water uptake of the chitosan-GPTMS guide tubes throughout a period 
of 7 days during which they were kept at 37oC and completely immersed in the PBS solution 
  
 
at pH 7.4. In the first two hours, the guide tubes quickly absorbed the fluids since the water 
uptake is nearly 1000% of the initial dry mass. After 24 hours, the water uptake of the guide 
tubes rises up to ~1400% and from this point on the water uptake decreases which may be 
due to mass loss. 
 
 
Figure 13 – Averaged values of water uptake (%) of the chitosan-GPTMS guide tubes as function of the 
period of soaking in PBS. 
 
 
4.2.4 Degree of crosslinking 
As mentioned before, GPTMS was used in this study as a crosslinking reagent at the time 
of preparation of the chitosan-GPTMS guide tubes. Their degree of crosslinking was 
calculated by Equation 2 previously described and a degree of crosslinking around 69% was 
obtained for chitosan-GPTMS samples. 
 
 
Figure 14 - Calibration curve of glycine. 
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Figure 15 - Optical absorbance of the chitosan powder and the chitosan-GPTMS guide tubes. 
  
4.2.5 Mechanical assay 
Dimensional stability and mechanical integrity of conduits are an important feature in 
tissue and biomedical engineering applications, because material often requires 
manipulation, and sample integrity must be maintained. In that sense, stress-strain curves 
were plotted and the Young modulus (E) calculated for both conditions at a fixed strain of 2% 
for dry and hydrated samples (Figure 16). It was observed that samples present an increase of 
the stress with increasing strain until material collapse occurs (Figure 17) Furthermore, 
hydrated samples present ultimate tensile stress lower than the one of the dry samples due 
to the amount of water that fills sample porous structure and probably works as a plasticizer 
agent, leading to a decrease of the Young modulus for the hydrated samples. Finally, the 
Young modulus of the hydrated samples (Table 2) summarizes the mechanical results 
obtained for chitosan samples in dried and hydrated states.  
 
Figure 16 - Strain-stress curves of both hydrated and dry samples. 
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 Strain at break (%) 
Ultimate Tensile 
Stress (MPa) 
E (MPa) 
Hydrated 6.64±3.49 0.02±0.02 0.19±0.05 
Dry 7.09±2.58 0.18±0.08 2.91±2.20 
Table 2 - Values of strain (%), stress (MPa) and Young modulus (E) (MPa) for both hydrated and dry 
samples. 
 
 
4.2.6 In vivo Testing 
4.2.6.1 EPT and WRL 
Table 3 (see Appendix) presents the results of motor deficit derived from EPT measures. 
Analyzing the results, it is possible to conclude that nerve transection (neurotmesis) caused a 
severe motor deficit in all experimental groups except in the Control group (Group 1). One 
week after the surgery, all rats in the six groups presented severe loss of hindlimb extension 
force except Group 1 where the sciatic nerve was un-injured. During the follow-up period of 
20 weeks, it can be observed that the motor deficit of all groups decreases, with a faster 
recovery along time in some groups than in others. However, in the Ch-GPTMS group there is 
no evidence of motor deficit decrease since the results concerning this group only go as far as 
week 4 post-surgery. The functional analysis of this experimental group is still being 
performed, since the preparation and characterization of the chitosan-GPTMS guide tubes 
was previously needed. Two-way ANOVA revealed a significant effect of time [F(11,176) = 
195.690, P < 0.001] and group [F(3,21) = 18.681, P = 0.000] in the results of motor deficit. 
Statistical analysis indicated that the recovery of motor function along the 20 weeks occurred 
faster in the End-to-end group (Group 3) followed by the Graft group (Group 4) and slower in 
both the PLGA group and in the Gap group (control group not included in the statistical 
analysis). At the end of follow-up, differences between the End-to-end group and the PLGA 
group (Group 5) were still significant, but no differences were observed between the PLGA 
group and the Graft group. 
Table 4 presents the data for the WRL tests. In the first week post-surgery, all animals 
presented severe loss of sensory function and all tests had to be interrupted at the selected 
cutoff time of 12 seconds except for Group 1. Throughout the follow-up period of 20 weeks, 
the nociception function was being recovered and at week 20 it was in the range of normal 
values (bellow 4.3 seconds) in all the groups, except for Group 2 (Gap), which didn’t present 
any recovery of the WRL, since the neurotmesis injury was not surgically repaired. Again, the 
Ch-GPTMS group has not yet reached the 20 week period but it has already shown some 
decrease of the WRL at week 4. Nociception recovered significantly along the following weeks 
[F(11,33) = 54.065; P = 0.000] except in the Gap group. Two way ANOVA also indicated 
significant differences between groups in the recovery of nociception [F(3,21) = 8.270; P = 
0.001], with the post hoc test revealing that the End-to-end group differed from the other 
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three groups (P < 0.05). At the end of 20 weeks, results of the hotplate test were similar in 
all four experimental treated groups. In the gap, untreated group (Group 2), no signs of 
recovery in sensory function were evident along 20 weeks of follow up (Table 4 – see 
Appendix). Values presented in Table 3 and Table 4 are plotted in Figure 17. 
 
 
Figure 17 - Mean Extensor Postural Thrust (EPT) and Withdrawal Reflex Latency (EPT) results for 20 
weeks follow-up. Values of Motor Deficit were obtained performing EPT test (A). Values in seconds (s) 
were obtained performing WRL test to evaluate the nocicpetive function (B). These tests have been 
performed pre-operatively (week 0), at week 1 and every 2 weeks after the surgical procedure until 
week 20, when the animals were sacrificed for morphological analysis. 
 
 
4.2.6.2 SFI and SSI 
Both SFI and SSI were evaluated only in a small number of animals and not for all the 
experimental groups. At week 0 (pre-operative) SFI was -7.4±5.4 in Group 2 (Gap, n=4). One 
week after surgeries, SFI became much more negative and it was -83.2±2.2 for group 4 
  
 
(Graft, n=6). This result indicates a profound impairment in foot and toes ground contact. By 
the end of the follow-up period, SFI values remained highly negative which indicates only a 
modest recovery of the foot placement after neurotmesis. At week 20, the PLGA group 
(Group 5, n=5) had a SFI value of -62.3±2.3 and Gap group had a SFI value of -82.5±4.3.64 
Variations on the SSI results were similar to SFI’s. By week 20, SSI values were -76.6±4.9 for 
Gap group.64 For the Ch-GPTMS group (Group 6, n=5) SFI was -55.2±0.0 in both week 1 and 
week 2 post-operative. At week 4, SFI became even more negative which translates the great 
impairment in foot and toes ground contact. As a matter of fact, it was verified in almost all 
experimental rats, autotomy, which limits the SFI test evaluation. On the other hand, the 
variations between the first two weeks after surgeries and week 4 were not as high for SSI. At 
week 1 and 2, SSI was -72.9±27.6 and at week 4 it was -69.5±19.2. Notice that in SFI test in 
Group 6, it was sometimes rather difficult or even impossible to gather measurements of the 
impaired hindlimb since its sciatic nerve was transected which results in a highly retracted 
hindlimb. 
 
 
Figure 18 - Rat footprints taken during the SSI test. On the left are represented the footprints taken on 
week 1 and week 2. On the right are represented the footprints taken on week 4. 
 
 
4.2.6.3 Stereological and histological analysis 
Table 5 (see Appendix) shows the results of the stereological comparison of density, total 
number, mean diameter, and myelin thickness of nerve fibers in the Control, End-to-end, 
Graft and PLGA groups. Statistical analysis by ANOVA showed that while the intergroup 
numerical differences in the fiber density were not statistically significant (P>0.05), 
intergroup differences in total fiber number were not significant (P>0.05) between Graft and 
PLGA groups but was significant (P<0.05) in these two groups. Yet, statistical analysis of 
numerical data on mean nerve fiber diameter and myelin thickness revealed statistically 
significant (P<0.05) differences between all groups regarding fiber diameter, while intergroup 
differences in myelin thickness were not significant (P>0.05).64 
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Figure 19 - Histological appearance of a normal rat sciatic nerve (Magnification: 1000x). 
 
 
4.3 Discussion 
In the present study, chitosan-GPTMS guide tubes were produced and a number of assays 
were performed in order to characterize them both mechanically and structurally. 
Furthermore, in vivo testing took place using the rat sciatic nerve as the experimental model. 
Peripheral nerve regeneration was assessed after a neurotmesis injury was induced. 
The FTIR spectrum provides information through band properties, frequencies and 
intensities and can be used to predict chemical processes, identify species and determine the 
increase in the number of certain entities from the increase in the area of the band.81 In 
Figure 12 is represented the FTIR spectrum of the chitosan-GPTMS guide tubes (A) and of the 
original chitosan powder (B). There are 3 peaks in the FTIR spectra of the chitosan-GPTMS 
guide tubes that are characteristic of the GPTMS monomer. The 2840 cm-1 peak is assigned to 
the methoxy group of the GPTMS and the 1192 and 914 cm-1 peaks are assigned to the epoxy 
group.80 By introducing silane groups into chitosan through the crosslinking reaction with 
GPTMS, it should be visible in the FTIR spectra a peak around 920 cm-1 that corresponds to 
the stretching band of Si-OH.84 
The ninhydrin reaction was used to quantitatively determine the amount of free amino 
groups, thus calculating the degree of crosslinking of the chitosan-GPTMS guide tubes, 
according to a method previously described.66 In this case, GPTMS, which is one of the silane-
coupling agents and is constituted by an epoxy group and methoxysilane groups, is the 
crosslinker.8,80,85 Of all the cyclic units of chitosan, 79% of them has an amino group that 
force-opens the epoxy group of GPTMS to form a –NH-O- bond.8 During the crosslinking 
reaction, the epoxy group is linked to the amino group of chitosan and the methoxysilane 
groups are hydrolyzed forming silanol groups. These are subjected to the construction of a 
siloxane network due to condensation. Furthermore, the negative charges of the silanol 
groups and the positive charges of the amino groups favor the crosslinking reaction.8,48,80,86 
  
 
Hence, the crosslinking in the chitosan-GPTMS guide tubes is achieved by two components: 
the epoxy and methoxysilane groups. In Figure 15 is represented the difference between the 
optical absorbance of the chitosan powder (non-crosslinked raw material) and the crosslinked 
guide tubes, being that the latter optical absorbance is rather lower than the first, which 
suggests that GPTMS worked as a crosslinking agent and the amount of crosslinking of the 
samples was 69%. 
Observing Figure 11, it becomes clear that the chitosan-GPTMS guide tubes are highly 
porous, which in some extent is due to the presence of GPTMS that has been shown to be 
responsible for the size of the pores.8 These chitosan-GPTMS structures were developed in 
order to be porous while preserving some mechanical strength. The combination of a more 
favorable porous microstructure and physicochemical properties, along with the presence of 
silicon ions may be responsible for the good results in post-traumatic nerve regeneration. 
Also, some degree of porosity is intended to allow for influx of low molecular nutrients 
required for nerve regeneration.49,87 In another study, it was shown that the pore size is 
strongly dependent on the freezing temperature, being that the size increased with the 
freezing temperature.8 
When developing structures of this kind, the mechanical strength is a factor to be 
considered in order to avoid problems during implantation and healing period such as 
collapsing and disintegration. The balance between hardness and flexibility should also be 
taken into consideration throughout their fabrication.84,88 Under physiological conditions, 
chitosan matrices have shown to have low mechanical strength and to be unable to maintain 
the predefined shape after implantation.69 One way to mechanically characterize the guide 
tubes was to plot strain-stress curves and to calculate their Young Modulus. In Figure 16 is 
possible to observe that the Young modulus (E), i.e. the elastic modulus, is lower for the 
hydrated samples, which means that when in an environment with fluids, the guide tubes are 
less rigid and more brittle. Thus, the guide tubes become prone to collapse than when dry. 
Since chitosan-GPTMS guide tubes are highly porous, it is only logic to assume that their 
water uptake would be high, which is in fact demonstrated in Figure 13 that shows that after 
only 2 h the water uptake is 1000% of the initial dry mass of the guide tubes. It is a known 
fact that in the center of the bridging bond between chitosan and GPTMS there is a –Si-O-Si 
bond that is prone to be hydrolyzed by the NaOH solution, by which the guide tubes are 
washed after the first lyophilization, into S-OH bonds. Hence, it is reasonable to assume that 
this would allow the reduction of the tight intermolecular bonds, leave hydrophilic groups 
exposed and consequently allow the swelling of the guide tubes when soaked in PBS.8 During 
the period of swelling, the porous structures are filled with PBS and sometimes go through a 
degradation process.8 At this point, the water will occupy the atomic level space in the 
matrix as well as the pores. This demonstrates the ability of the matrix of the chitosan-
GPTMS guide tubes to hold water, which is higher than the ability of the original 
chitosan.8,49,89 These observations can be correlated with the SEM images of the matrix of the 
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guide tubes, which are very porous, thus confirming the high values of water uptake. When 
comparing these results with those of PLGA guide tubes, there are some differences since 
their water uptake occurred rapidly in the first 24 h and then stabilized until the end of the 
72 h period.64 
The rat sciatic nerve has been the most commonly used experimental animal model in 
studies concerning peripheral nerve regeneration due to its reliability.90,91 Also, this 
experimental model provides a nerve trunk with adequate length and space at the mid-thigh 
for surgical manipulation and implantation of grafts or guide tubes.92 Both functional and 
morphological assessments are evaluation tools when it is important to quantify the 
regeneration of the peripheral nerve considering different therapeutic strategies. Different 
methods should be used in order to perform an overall assessment of nerve function.87 The 
investigation of nerve morphology can provide important information on various aspects of 
the regeneration process which is related to nerve function.87 Chitosan-GPTMS structures 
have shown in in vivo studies an improved nerve fiber regeneration and functional recovery in 
neurotmesis injuries. Also, the main morphological predictors of nerve regeneration (number 
of fibers, axon and fiber size, and myelin thickness) were significantly improved when the rat 
sciatic nerve was reconstructed with such structures. 27,49,50 
The EPT and WRL tests have been proven to be reliable, valid and highly efficient tests 
when it comes to determine the functional recovery following sciatic nerve injury.93 The EPT 
and WRL measurements also provide a quantitative measurement of motor and sensitive 
function recoveries, respectively, they are simple, easy to execute, and give consistently less 
variation between measurements.68 Also, SFI tests provide a quantitative measure of degree 
of functional deficit, but can be cumbersome, messy, time consuming, and variable, 
especially considering the evaluation of neurotmesis injuries recoveries, since autotomy is 
frequently observed in these experimental animals. It also provides only one integrated 
measure of function.68 
The surgical procedures allowed evaluating the performance of the chitosan-GPTMS guide 
tubes when in contact with fluids. The main observation was the friability of the guide tubes 
in a way that it was clear that the structure was fragile, which in some ways is consistent 
with the previously mentioned conclusions about the porosity, water uptake and mechanical 
strength. However, their mechanical and structural properties can be improved if a optimal 
ratio is achieved between chitosan and GPTMS at the time of preparation of the guide 
tubes.69 This problem with the easiness to suture the guide tubes to the nerve stumps didn’t 
come as problem when using PLGA guide tubes, since in this case sutures held without 
difficulties. However, greater care had to be taken in order to ensure the integrity of the 
guide tube after implantation.64 
 
4.4 Conclusions 
Recently, the efficacy of biomaterials and cellular systems association in the treatment of 
sciatic nerve axonotmesis and neurotmesis injury was tested in vivo using the rat model. 
  
 
Animal models are used to investigate and better understand the process of a condition or a 
disease. An important aspect of these models is their reliability. The rat sciatic nerve has 
been commonly used as an experimental model in studies concerning the peripheral nerve 
regeneration but the functional assessment in this animal model is still a challenge.27,54 The 
rat sciatic nerve animal model provides a not so expensive source of mammalian nervous 
tissue easy to manipulate and to work with. This model is used to evaluate both the motor 
and the sensory nerve function.54 Another aspect that makes this animal model so widely used 
is the widespread availability and the distribution of the rat nerve trunks, which is similar to 
humans. Also, the induction of a crush injury in a rat sciatic nerve provides a very realistic 
and useful model of damage for the study of the role of numerous factors in regenerative 
processes.49 
Following transection, axons show staggered regeneration and may take substantial time 
to cross the injured site and enter the distal nerve stump. However delayed axonal 
elongation might be caused by growth inhibition originated from the distal nerve itself, 
growth-stimulating influences may overcome axons stagger. As a potential source of growth 
promoting signals, MSCs transplantation is expected to give a positive outcome, so the future 
association of this cellular system to the described chitosan-GPTMS guide tubes should be 
tested in the near future. The guide tube was developed as a hybrid of chitosan by adding a 
crosslinker agent, GPTMS. A synergistic effect of an extra permeability and physicochemical 
properties of chitosan may be responsible for the good results in post-traumatic nerve 
regeneration promotion that might be observed in the sciatic nerve after neurotmesis in the 
end of the healing period of 20 weeks. This biomaterial may not just work as a simple 
mechanical device but instead may induce nerve regeneration. The neuroregenerative 
properties of chitosan may be explained by the effect on SCs proliferation, axon elongation 
and myelinization. 49,62,80,86 Data also showed that PLC does not deleteriously interfere with 
the nerve regeneration process, as a matter of fact, the information on the effectiveness of 
PLC membranes and tube-guides for allowing nerve regeneration was already provided 
experimentally and with patients.87,94 The MSCs isolated from the Wharton´s jelly combined 
with PLC and chitosan-GPTMS guide tubes might be a potentially valuable tool to improve 
clinical outcome especially after trauma to sensory nerves, such as digital nerves. 
The goals initially proposed for this experimental work were accomplished. From the 
mechanical and structural analysis, the chitosan-GPTMS guide tubes seem to be suitable and 
in some way ideal to promote the nerve regeneration after a neurotmesis injury. 
 
 
4.5 Future Work 
The process of preparation of the chitosan-GPTMS guide tubes has yet alterations and 
improvements to be made in order to reach optimal conditions and better results. For 
instance, a modification in the ratio between the amount of polymer and crosslinker can be 
 44  
44 
 
made during the preparation of the guide tubes. Also, a mass loss test can be performed both 
at physiological and acid pH in order to assess the degradation rate of the guide tubes. A 
sterilization method can be considered so a comparison between sterilized and non sterilized 
samples could be made and the differences registered. Some investigators have already 
sterilized chitosan-GPTMS membranes for in vivo testing with ethylene oxide gas but a gamma 
radiation sterilization can also be considered.87,94 Regarding the in vivo tests, the follow-up of 
the rats implanted with the chitosan-GPTMS guide tubes will be continued until week 20. As 
an attempt to improve the performance of the chitosan-GPTMS guide tubes, MSCs should be 
combined with these structures since it has been proven to be a successful approach that led 
to even better results.27,62 
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Appendix 
 
 
 
 
Values of motor deficit, presented between 0 and 1, were obtained performing EPT test. This test has been performed preoperatively (week 0), at week 1, and every 2 weeks after the surgical procedure until week 20, 
when the animals were sacrificed for morphological analysis. Results are presented as mean and standard deviation (SD). In group 2 (Gap), the nerve with neurotmesis was left unrepaired. In group 3 (End-to-end), 
immediate coaptation with 7/0 monofilament nylon sutures of the two injured nerve endings was performed.  In group 4 (Graft), the sciatic nerve was transected immediately above the terminal nerve ramification and in 
a 10-mm distal point. In group 5 (PLGA), the proximal and distal nerve stumps were inserted 3 mm into the PLGA guide tubes and held in place, maintaining a nerve gap of 10 mm. The nerve graft obtained, with a length 
of 10mm, was inverted 1800 and sutured with 7/0 monofilament nylon. In group 1, the sciatic nerve was un-injured and served as control (Control). In group 6 (Ch-GPTMS, n=5), the proximal and distal nerve stumps were 
inserted into the guide tubes and held in place. All groups n=6. 
 
Group Week 0 Week 1 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 Week 14 Week 16 Week 18 Week 20 
Control 0.06±0.03 0.07±0.01 0.05±0.03 0.06±0.02 0.06±0.01 0.05±0.01 0.05±0.02 0.05±0.01 0.04±0.02 0.05±0.02 0.04±0.03 0.03±0.02 
Gap 0.08±0.01 0.93±0.04 0.91±0.01 0.90±0.02 0.89±0.09 0.91±0.05 0.98±0.02 0.88±0.06 0.86±0.04 0.88±0.07 0.91±0.06 0.91±0.04 
End-to-end 0.07±0.01 0.90±0.07 0.87±0.06 0.78±0.08 0.74±0.09 0.63±0.16 0.53±0.12 0.45±0.13 0.50±0.12 0.39±0.07 0.37±0.04 0.40±0.07 
Graft 0.03±0.07 0.90±0.04 0.89±0.03 0.85±0.05 0.77±0.01 0.72±0.06 0.64±0.05 0.66±0.03 0.60±0.09 0.53±0.08 0.54±0.03 0.52±0.03 
PLGA 0.08±0.01 0.93±0.06 0.86±0.10 0.86±0.09 0.85±0.05 0.84±0.08 0.81±0.07 0.79±0.05 0.71±0.05 0.70±0.10 0.67±0.12 0.55±0.07 
Ch-GPTMS 0.07±0.01 0.92±0.03 0.92±0.03 0.94±0.04         
Table 3 - Results of the Extensor Postural Thrust (EPT). 
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Values in seconds (s) were obtained performing WRL test to evaluate the nociceptive function. This test has been performed preoperatively (week 0), at week 1, and every 2 weeks after the surgical procedure until week 
20, when the animals were sacrificed for morphological analysis. Results are presented as mean and standard deviation (SD). In group 2 (Gap), the nerve with neurotmesis was left unrepaired. In group 3 (End-to-end), 
immediate coaptation with 7/0 monofilament nylon sutures of the two injured nerve endings was performed.  In group 4 (Graft), the sciatic nerve was transected immediately above the terminal nerve ramification and in 
a 10-mm distal point. In group 5 (PLGA), the proximal and distal nerve stumps were inserted 3 mm into the PLGA guide tubes and held in place, maintaining a nerve gap of 10 mm. The nerve graft obtained, with a length 
of 10mm, was inverted 1800 and sutured with 7/0 monofilament nylon. In group 1, the sciatic nerve was un-injured and served as control (Control). In group 6 (Ch-GPTMS, n=5), the proximal and distal nerve stumps were 
inserted into the guide tubes and held in place. All other groups n=6. 
 
 
Table 5 - Stereological quantitative assessment of density, total number, diameter and myelin thickness of regenerated sciatic nerve fibers at week 20 after neurotmesis. 
Values are presented as mean ± SD. 
 
Group Fiber density (N/mm2) Fiber number (n) Fiber diameter (µm) Myelin thickness (µm) 
Control 15.905±2.87 7,666±1.90 6.66±0.12 1.19±0.03 
End-to-end 20,612±1,067 14,624±1,642 4.06±0.30 0.58±0.03 
Graft 26,037±1,086 13,212±610 4.02±0.11 0.48±0.03 
PLGA 21,982±1,927 10,532±2,195 3.49±0.11 0.40±0.02 
 
Group Week 0 Week 1 Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 Week 14 Week 16 Week 18 Week 20 
Control 1.50±0.55 1.17±0.41 1.83±0.41 1.50±0.55 1.83±0.75 2.00±0.63 1.50±0.55 1.67±0.52 1.83±0.75 1.83±0.41 2.00±0.63 1.67±0.52 
Gap 1.8±0.50 12±0.00 12±0.00 12±0.00 12±0.00 12±0.00 12±0.00 12±0.00 12±0.00 12±0.00 12±0.00 12±0.00 
End-to-end 2.50±0.84 12.00±0.00 6.83±4.22 6.83±4.49 7.67±3.39 3.33±1.37 5.33±3.08 4.83±3.82 3.83±0.98 4.83±1.83 3.17±1.33 2.83±0.98 
Graft 1.8±0.40 12±0.00 12±0.00 12±0.00 12±0.00 12±0.00 6.7±2.94 5.5±2.35 4.0±1.55 3.8±1.60 3.3±0.42 3.3±0.21 
PLGA 1.7±0.52 12±0.00 12±0.00 8.5±4.46 8.8±4.22 8.8±3.71 5.5±4.46 7.3±3.08 6.7±3.33 5.8±4.12 5.3±1.86 3.8±1.72 
Ch-GPTMS 2.29±0.95 12.0±0.00 12.0±0.00 11.4±0.76         
Table 4 - Results of the Withdrawal Reflex Latency (WRL). 
